ANI Pharmaceuticals (NASDAQ:ANIP) Coverage Initiated by Analysts at HC Wainwright

Analysts at HC Wainwright began coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) in a report issued on Thursday, MarketBeat.com reports. The firm set a "buy" rating and a $84.00 price target on the specialty pharmaceutical company's stock. HC Wainwright's target price would suggest a potential upside of 29.09% from the company's previous close.

Several other equities research analysts have also recently commented on ANIP. Wall Street Zen cut shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday, April 24th. Guggenheim reiterated a "buy" rating and set a $86.00 price target on shares of ANI Pharmaceuticals in a report on Monday, May 12th. Truist Financial lifted their price target on ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a "hold" rating in a report on Monday, April 21st. JPMorgan Chase & Co. initiated coverage on ANI Pharmaceuticals in a report on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 target price for the company. Finally, Jefferies Financial Group assumed coverage on ANI Pharmaceuticals in a report on Friday, March 14th. They issued a "buy" rating and a $80.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $78.88.

ANI Pharmaceuticals Stock Performance

ANIP stock traded down $1.03 during mid-day trading on Thursday, reaching $65.07. The company had a trading volume of 100,259 shares, compared to its average volume of 315,045. The company has a quick ratio of 1.98, a current ratio of 2.66 and a debt-to-equity ratio of 1.46. The stock has a market capitalization of $1.41 billion, a P/E ratio of -51.24 and a beta of 0.57. ANI Pharmaceuticals has a one year low of $52.50 and a one year high of $77.00. The stock's 50-day simple moving average is $63.47 and its two-hundred day simple moving average is $62.19.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings data on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share for the quarter, beating analysts' consensus estimates of $1.37 by $0.33. ANI Pharmaceuticals had a negative net margin of 3.12% and a positive return on equity of 21.35%. The business had revenue of $197.12 million for the quarter, compared to analysts' expectations of $179.75 million. During the same period in the previous year, the business earned $0.82 earnings per share. The company's revenue was up 43.4% on a year-over-year basis. Research analysts anticipate that ANI Pharmaceuticals will post 3.86 EPS for the current year.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Ori Gutwerg sold 881 shares of the company's stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $60.07, for a total value of $52,921.67. Following the sale, the senior vice president directly owned 89,897 shares in the company, valued at $5,400,112.79. This represents a 0.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Meredith Cook sold 400 shares of the company's stock in a transaction on Monday, April 14th. The shares were sold at an average price of $68.96, for a total value of $27,584.00. Following the completion of the sale, the vice president owned 80,145 shares in the company, valued at $5,526,799.20. This trade represents a 0.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,681 shares of company stock worth $346,854 over the last three months. Company insiders own 11.10% of the company's stock.

Institutional Trading of ANI Pharmaceuticals

Large investors have recently bought and sold shares of the stock. Advisors Asset Management Inc. acquired a new position in ANI Pharmaceuticals in the first quarter worth $28,000. US Bancorp DE boosted its stake in ANI Pharmaceuticals by 842.9% in the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock worth $33,000 after purchasing an additional 531 shares in the last quarter. National Bank of Canada FI acquired a new position in ANI Pharmaceuticals in the first quarter worth $79,000. GAMMA Investing LLC boosted its stake in ANI Pharmaceuticals by 163.8% in the first quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock worth $95,000 after purchasing an additional 881 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in ANI Pharmaceuticals in the fourth quarter worth $166,000. 76.05% of the stock is currently owned by institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.